275 related articles for article (PubMed ID: 36908859)
1. Novel insights into histone lysine methyltransferases in cancer therapy: From epigenetic regulation to selective drugs.
Liao Q; Yang J; Ge S; Chai P; Fan J; Jia R
J Pharm Anal; 2023 Feb; 13(2):127-141. PubMed ID: 36908859
[TBL] [Abstract][Full Text] [Related]
2. Epigenetic therapy in gastrointestinal cancer: the right combination.
Abdelfatah E; Kerner Z; Nanda N; Ahuja N
Therap Adv Gastroenterol; 2016 Jul; 9(4):560-79. PubMed ID: 27366224
[TBL] [Abstract][Full Text] [Related]
3. The pharmacoepigenetic paradigm in cancer treatment.
Ocaña-Paredes B; Rivera-Orellana S; Ramírez-Sánchez D; Montalvo-Guerrero J; Freire MP; Espinoza-Ferrao S; Altamirano-Colina A; Echeverría-Espinoza P; Ramos-Medina MJ; Echeverría-Garcés G; Granda-Moncayo D; Jácome-Alvarado A; Andrade MG; López-Cortés A
Front Pharmacol; 2024; 15():1381168. PubMed ID: 38720770
[TBL] [Abstract][Full Text] [Related]
4. Current trends in clinical trials and the development of small molecule epigenetic inhibitors as cancer therapeutics.
Zohourian N; Brown JA
Epigenomics; 2024 Apr; ():. PubMed ID: 38639711
[TBL] [Abstract][Full Text] [Related]
5. New targeted therapies for breast cancer: A focus on tumor microenvironmental signals and chemoresistant breast cancers.
Nwabo Kamdje AH; Seke Etet PF; Vecchio L; Tagne RS; Amvene JM; Muller JM; Krampera M; Lukong KE
World J Clin Cases; 2014 Dec; 2(12):769-86. PubMed ID: 25516852
[TBL] [Abstract][Full Text] [Related]
6. lncRNAs-EZH2 interaction as promising therapeutic target in cutaneous melanoma.
Wozniak M; Czyz M
Front Mol Biosci; 2023; 10():1170026. PubMed ID: 37325482
[TBL] [Abstract][Full Text] [Related]
7. H3 histone methylation landscape in male urogenital cancers: from molecular mechanisms to epigenetic biomarkers and therapeutic targets.
Burlibasa L; Nicu AT; Chifiriuc MC; Medar C; Petrescu A; Jinga V; Stoica I
Front Cell Dev Biol; 2023; 11():1181764. PubMed ID: 37228649
[TBL] [Abstract][Full Text] [Related]
8. Post-translational modifications of histones: Mechanisms, biological functions, and therapeutic targets.
Liu R; Wu J; Guo H; Yao W; Li S; Lu Y; Jia Y; Liang X; Tang J; Zhang H
MedComm (2020); 2023 Jun; 4(3):e292. PubMed ID: 37220590
[TBL] [Abstract][Full Text] [Related]
9. Super-enhancers complexes zoom in transcription in cancer.
Wang M; Chen Q; Wang S; Xie H; Liu J; Huang R; Xiang Y; Jiang Y; Tian D; Bian E
J Exp Clin Cancer Res; 2023 Jul; 42(1):183. PubMed ID: 37501079
[TBL] [Abstract][Full Text] [Related]
10. The evaluation of six genes combined value in glioma diagnosis and prognosis.
Lin P; He L; Tian N; Qi X
J Cancer Res Clin Oncol; 2023 Oct; 149(13):12413-12433. PubMed ID: 37439825
[TBL] [Abstract][Full Text] [Related]
11. Histone modifications in drug-resistant cancers: From a cancer stem cell and immune evasion perspective.
Jin ML; Jeong KW
Exp Mol Med; 2023 Jul; 55(7):1333-1347. PubMed ID: 37394580
[TBL] [Abstract][Full Text] [Related]
12. Metformin and cancer hallmarks: shedding new lights on therapeutic repurposing.
Hua Y; Zheng Y; Yao Y; Jia R; Ge S; Zhuang A
J Transl Med; 2023 Jun; 21(1):403. PubMed ID: 37344841
[TBL] [Abstract][Full Text] [Related]
13. Targeting CDK9 with selective inhibitors or degraders in tumor therapy: an overview of recent developments.
Xiao L; Liu Y; Chen H; Shen L
Cancer Biol Ther; 2023 Dec; 24(1):2219470. PubMed ID: 37272701
[TBL] [Abstract][Full Text] [Related]
14. NSUN2-mediated m
Zuo S; Li L; Wen X; Gu X; Zhuang A; Li R; Ye F; Ge S; Fan X; Fan J; Chai P; Lu L
Clin Transl Med; 2023 May; 13(5):e1273. PubMed ID: 37228185
[TBL] [Abstract][Full Text] [Related]
15. The roles of EZH2 in cancer and its inhibitors.
Liu Y; Yang Q
Med Oncol; 2023 May; 40(6):167. PubMed ID: 37148376
[TBL] [Abstract][Full Text] [Related]
16. Protein posttranslational modifications in health and diseases: Functions, regulatory mechanisms, and therapeutic implications.
Zhong Q; Xiao X; Qiu Y; Xu Z; Chen C; Chong B; Zhao X; Hai S; Li S; An Z; Dai L
MedComm (2020); 2023 Jun; 4(3):e261. PubMed ID: 37143582
[TBL] [Abstract][Full Text] [Related]
17. An Update of Epigenetic Drugs for the Treatment of Cancers and Brain Diseases: A Comprehensive Review.
Sahafnejad Z; Ramazi S; Allahverdi A
Genes (Basel); 2023 Apr; 14(4):. PubMed ID: 37107631
[TBL] [Abstract][Full Text] [Related]
18. Machine learning-based integration develops an immune-related risk model for predicting prognosis of high-grade serous ovarian cancer and providing therapeutic strategies.
Wu Q; Tian R; He X; Liu J; Ou C; Li Y; Fu X
Front Immunol; 2023; 14():1164408. PubMed ID: 37090728
[TBL] [Abstract][Full Text] [Related]
19. The engagement of histone lysine methyltransferases with nucleosomes: structural basis, regulatory mechanisms, and therapeutic implications.
Li Y; Ge K; Li T; Cai R; Chen Y
Protein Cell; 2023 Apr; 14(3):165-179. PubMed ID: 37051671
[TBL] [Abstract][Full Text] [Related]
20. Histone methyltransferase SETD2: An epigenetic driver in clear cell renal cell carcinoma.
Yu M; Qian K; Wang G; Xiao Y; Zhu Y; Ju L
Front Oncol; 2023; 13():1114461. PubMed ID: 37025591
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
